John P. Kenny
Net Worth

Last updated:

What is John P. Kenny net worth?

The estimated net worth of Mr. John P. Kenny is at least $23,846,381 as of 27 Jun 2022. He owns shares worth $9,006,500 as insider, has earned $4,948,741 from insider trading and has received compensation worth at least $9,891,140 in Meridian Bioscience, Inc. and Meridian Bioscience, Inc..

What is the salary of John P. Kenny?

Mr. John P. Kenny salary is $1,510,000 per year as Pres, Chief Executive Officer & Director in Meridian Bioscience, Inc.. He also receives $831,140 as Pres, Chief Executive Officer, Executive Vice President of Diagnostics Bus. Unit & Director in Meridian Bioscience, Inc..

How old is John P. Kenny?

Mr. John P. Kenny is 57 years old, born in 1968.

What stocks does John P. Kenny currently own?

As insider, Mr. John P. Kenny owns shares in one company:

Company Title Shares Price per share Total value
Meridian Bioscience, Inc. (VIVO) Pres, Chief Executive Officer & Director 265,131 $33.97 $9,006,500

What does Meridian Bioscience, Inc. do?

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

John P. Kenny insider trading

Meridian Bioscience, Inc.

Mr. John P. Kenny has made 11 insider trades between 2019-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 68,288 units of VIVO stock on 8 Feb 2021. As of 27 Jun 2022 he still owns at least 265,131 units of VIVO stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Options (Right to Buy) 13,559 $10.1 $136,946
Sale
Common Stock 61,437 $30.39 $1,866,763
Option
Common Stock 61,437 $10.1 $620,514
Option
Stock Options (Right to Buy) 61,437 $10.1 $620,514
Option
Common Stock 13,559 $10.1 $136,946
Sale
Common Stock 13,559 $30.01 $406,838
Option
Stock Options (Right to Buy) 44,651 $14.5 $647,440
Option
Stock Options (Right to Buy) 5,349 $14.5 $77,561
Option
Stock Options (Right to Buy) 14,607 $10.1 $147,531
Sale
Common Stock 19,956 $29.98 $598,201
Option
Common Stock 5,349 $14.5 $77,561
Option
Common Stock 14,607 $10.1 $147,531
Option
Common Stock 44,651 $14.5 $647,440
Sale
Common Stock 44,651 $29.72 $1,326,938
Sale
Common Stock 30,000 $25 $750,000
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 2,359 N/A N/A
Option
Stock Options (Right to Buy) 2,082 N/A N/A
Option
Common Stock 2,082 N/A N/A
Option
Common Stock 23,097 N/A N/A
Option
Stock Options (Right to Buy) 23,097 N/A N/A
Sale
Common Stock 26,181 N/A N/A
Option
Common Stock 1,164 N/A N/A
Option
Stock Options (Right to Buy) 1,164 N/A N/A
Sale
Common Stock 1,320 N/A N/A
Option
Common Stock 66,134 $12.3 $813,448
Option
Stock Options (Right to Buy) 66,134 N/A N/A
Option
Common Stock 66,134 N/A N/A
Sale
Common Stock 68,288 N/A N/A
Sale
Common Stock 40,000 N/A N/A
Purchase
Common Stock 30,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 20,000 N/A N/A
Purchase
Common Stock 20,000 N/A N/A

Meridian Bioscience key executives

Meridian Bioscience, Inc. executives and other stock owners filed with the SEC: